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Abstract: Surgery is a critical period in the survival of patients with cancer. While resective
surgery of primary tumors has shown to prolong the life of these patients, it can also promote
mechanisms associated with metastatic progression. During surgery, patients require general
and sometimes local anesthetics that also modulate mechanisms that can favor or reduce
metastasis. In this narrative review, we summarized the evidence about the impact of local,
regional and general anesthesia on metastatic mechanisms and the survival of patients. The
available evidence suggests that cancer recurrence is not significantly impacted by neither
regional anesthesia nor volatile or total intravenous anesthesia.
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Introduction
Cancer is a major cause of mortality worldwide with an estimated 9.6 million
deaths per year.1 Lung, colorectal, stomach and liver are the most common types of
cancer and account for nearly half of cancer-related deaths. By 2040, it is estimated
that there will be approximately 30 million new cases of cancer.1 It is projected that
a large proportion of patients will need surgery for tumor resection despite rapid
and substantial advances in treatments, including chemotherapy, targeted therapy,
radiotherapy, and immunotherapy.
Surgery causes the local and systemic release of inflammatory mediators and
promotes high levels of angiogenesis. Also, surgery is associated with high con-
centrations of circulating catecholamines and immunosuppression that can last for
days or weeks postoperatively, making this a period of high vulnerability for
complications and tumor progression.2,3 Some evidence suggests that certain anes-
thetics or anesthesia techniques may also affect the growth of the so-called minimal
residual disease.4,5 Total intravenous anesthesia (TIVA) with propofol was asso-
ciated with prolonged overall survival in patients with metastatic and non-meta-
static cancers.6 Local anesthetics and regional anesthesia can also modify cancer
progression by limiting inflammation, immunosuppression, and angiogenesis.4,7,8
However, a recently published randomized controlled trial concluded that compared
to sevoflurane-based general anesthesia, regional anesthesia did not improve the
survival nor reduced recurrences after breast cancer surgery.9
Investigators have hypothesized that the technique of general anesthesia (total
intravenous vs volatile-based or regional anesthesia) has a significant impact on
caner progression. In this narrative review, we will discuss the evidence of the
impact of different anesthetics and anesthesia techniques on metastatic progression
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after surgery. Our work will include current basic, transla-
tional and clinical studies addressing the effects and asso-
ciation between different anesthetics and cancer
progression.
Perioperative Metastasis Formation
The growth of metastatic colonies outside the primary
tumor is a multi-step process. Colonization of distant
sites by circulating tumor cells (CTCs) is a rate-limiting
step during the metastatic process. In general, it is well
accepted that metastasis may be part of a dominant clonal
subpopulation that originated within the primary tumor.10
By virtue of tumor-secreted factors and tumor-secreted
exosomes, the microenvironment of distant organ sites is
modified into prometastatic niches that contain recruited
stem cells and stromal cells.11
A critical event in the metastasis process is the epithe-
lial-mesenchymal transition (EMT) that CTCs undergo to
increase mobility and invasiveness (Figure 1). The EMT
process is orchestrated by transcription factors (ie, Snail,
Slug, Twist, and Zeb1) that, in turn, respond to extracel-
lular molecular signals occurring in the nearby tumor
stroma such as inflammation.12 Once in the bloodstream,
CTCs interact with other cells, including platelets and
lymphocytes. Platelets can provide shelter to CTCs and
hide them from lymphocytes such as natural killer (NK)
cells. Also, activated platelets can release soluble media-
tors such as transforming-growth factor beta (TGF-β),
platelet-derived growth factor (PDGF), and adenosine tri-
phosphate (ATP). These factors are known to suppress the
killing activity of NK cells and enhance vascular
permeability.12 Once CTCs extravasate via transendothe-
lial migration (TEM), they find the extracellular tissue
stroma where they may reside and proliferate. Some of
those cells in the new forming metastatic colony retain
features of cancer stem cells (CSC), which have tumor-
initiating ability and can drive colony expansion.12
It is speculated that micrometastasis or dormant colo-
nies are contained by immune surveillance or by the lack
of supporting factors that can sustain cell proliferation.13
Thus, the transition from single cell or colony of cells to
micrometastasis to clinically relevant metastasis can take
months to years.12,14 Remarkably, surgery can facilitate
the homing of CTCs and growth of micrometastasis by
releasing cytokines, angiogenic factors, and catechola-
mines. In mice, surgery-induced inflammation promoted
Figure 1 Perioperative events that influence tumor metastasis and cancer recurrence. Surgery for tumor resection triggers the release of catecholamines, immunosuppres-
sion, and angiogenesis. It has been speculated that these factors facilitate epithelial-mesenchymal transition (EMT) and promote a conducive microenvironment (tumor niche)
for cells to migrate, invade and proliferate.
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the outgrowth of T cell restricted distant tumors by mobi-
lizing myeloid cells and recruiting tumor-associated
macrophages.15
Neutrophil extracellular traps (NETs) has been recog-
nized as a mechanism that facilitates colonies formation.
NETs are web-like structures formed by DNA fragments
and proteins that can sequester CTCs.16,17 In mice, surgery
promoted NETs and micrometastasis. When mice were
treated daily with DNAase after surgery, it reduced
tumor growth.16 Circulating neutrophils entrapped in
clumps formed by platelets or in the extracellular matrix
can also provide a conducive environment for CTCs to
survive by further suppressing the activity of NK cells.12
Several studies have shown a decrease in the number
and function of circulating NK cells after surgery.3
Subsequently, investigations revealed that surgery-induced
reduction in circulating NK killing activity could promote
metastasis (Figure 1).18 Interestingly, it has been demon-
strated that the transcriptome profile of circulating NK
cells is significantly different from NK cells located in
metastasis suggesting that the role of NK cells in the
micrometastatic niche during surgery might be different
from those circulating.19
It is worth considering that the metastatic process is
also affected by factors including the use, timing, and
completion of adjuvant therapies (ie, chemotherapy, radia-
tion, and immunotherapies). For instance, it is now well
understood that for some malignancies, delaying the return
to oncological therapies after surgery has a significant
impact on patients’ survival.20 Another important factor
associated with cancer progression is the occurrence of
complications in the postoperative period and periopera-
tive blood transfusions.21,22 Therefore, it has been sug-
gested that patients undergoing cancer surgery should be
evaluated and treated by a multidisciplinary team dedi-
cated to assess modifiable risks and propose a coordinated
plan of measures (ie, anemia treatment) tailored to reduce
postoperative complications and accelerate recovery.23
In the following sections, we will discuss how anes-
thetics may or may not interfere with the process involved
in the metastatic process and metastatic cancer
progression.
Local Anesthetics
Local anesthetics can act on several steps of the metastatic
process (Figure 2). The administration of intravenous lido-
caine (1.5 mg/kg followed by infusion of 2 mg/kg) under
sevoflurane anesthesia reduced postoperative lung
metastasis by decreasing serum concentrations of the
metalloproteinase (MMP)-2 in a murine surgical breast
cancer model.24,25 It was speculated that changes in
MMP-2 resulted in a reduced ability of CTCs to form
metastasis.24 Local anesthetics also impair the movement
of malignant cells in vitro.26,27 As an example, ropivacaine
inhibited migration and invasion of esophageal and color-
ectal cancer cells.26 Although, the anti-metastatic effects
of ropivacaine in esophageal cancer cells were indepen-
dent of voltage-gated sodium channel (VGSCs) blockade
and mediated by inhibition of RhoA, Rac1 and Ras, they
were dependent on Nav1.5 blockade in colorectal cancer
cells.26,28
VGSCs regulate the metastatic activity of cancer cells.
These channels are located in the cell membrane, in parti-
cular in cellular structures called invadopodia, which are
essential for degrading the extracellular matrix.29 In the
invadopodia, VSGCs promote polymerization of actin fila-
ments via Src signaling.29 In vitro studies demonstrate that
downregulation of VSGCs via shRNA inhibits tumor inva-
sion by blocking the invadopodia.30
Local anesthetics have shown anti-angiogenic effects.
Lidocaine (30 mg/kg) inhibited tumor growth in mice
bearing melanoma tumors by inducing apoptosis in
endothelial cells.31 In these cells, lidocaine suppressed
VEGF-increased phosphorylation of VEGF receptor 2.31
Similarly ropivacaine induced apoptosis on tumor-asso-
ciated endothelial cells by inducing mitochondrial
dysfunction.32 Local anesthetics also modulate inflamma-
tion (Figure 3). Notably, lidocaine reduced pro-inflamma-
tory cytokines [ie, tumor necrosis factor (TNFα) and
interleukin-6 (IL-)] in a mice model having breast cancer
surgery.33 Furthermore, lidocaine and ropivacaine inhib-
ited migration and invasion of lung cancer cells by inhibit-
ing TNFα- induced phosphorylation of Src and reducing
the expression of ICAM-1 (glycoprotein essential for cel-
lular adhesion).34,35 A reduction in the concentrations of
pro-inflammatory concentrations is observed in humans
receiving intravenous lidocaine during surgery.36
Increased vascular permeability, as it occurs during
periods of exaggerated inflammation, facilitates TEM and
can promote the implant of metastatic cells. The intrave-
nous administration of lidocaine (1 and 3 mg/kg) to mice
inoculated with LPS significantly reduced lung permeabil-
ity. The postulated mechanisms included a reduction of
inflammatory cytokines (TNFα, IL-6, and MCP-1) and
impairment of antigen presentation, a process done by
dendritic cells (DC) (Figure 3).37,38 As an example,
Dovepress Cata et al
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lidocaine inhibited the expression of proinflammatory
cytokines in bone marrow-derived DC that were stimu-
lated with LPS.38
Inflammation also induces DNA methylation, a
mechanism linked with metastasis.39,40 Local anesthetics
such as lidocaine and ropivacaine induce, in vitro, DNA
demethylation in breast cancer cells which correlates with
the overexpression of the tumor suppressor genes (RARB2
and RASSF-1A).41–43 Lidocaine also induces modulation
of microRNAs.44–47 Treatment of lung cancer cells with 8
mM of lidocaine significantly increased the expression of
miR-539, which then induced the downregulation of the
epidermal growth factor receptor (EGFR) and suppressed
migration and invasion.45 The intravenous injection of
lidocaine (1.5 mg/kg) to mice bearing retinoblastoma
caused significant tumor reduction by inducing the expres-
sion of miR520a-3p and inhibiting EGFR.46 MicroRNAs
are also involved in chemo-resistance. Lidocaine, in vitro,
inhibited the expression of miR-21 and sensitized chemo-
resistant lung cancer cells to cisplatin.48 On the other hand,
lidocaine by inducing the expression of miR-493 down-
regulated the transcription factor Sox-4, which ultimately
sensitized melanoma cells to the effect of 5-fluorouracil.49
Another described mechanism that can contribute to
the anti-metastatic effects of local anesthetics include the
induction of oxidative stress, and a reduced formation of
MMP-9.30,34,35,50,51 Local anesthetics act on different
components of the innate and adaptive immune system
has been investigated experimentally and in humans. We
demonstrated that lidocaine in clinically relevant concen-
trations increased the in vitro cytotoxic activity of NK
cells by stimulating the release of perforins
(Figure 3).52,53 In humans with abdominal pain, an intra-
venous injection of 1 mg/kg of lidocaine preserves the
count and function of circulating NK cells.54 Few studies
have investigated the impact of intravenous lidocaine on
lymphocytes counts or function during and after oncologic
surgery.54,55 Wang et al conducted a randomized
Figure 2 Several mechanisms have been associated with the anti-metastatic effects of local anesthetics. Intracellular they inhibit signaling events linked to angiogenesis,
migration, and invasion.
Abbreviation: VEGF, vascular endothelial growth factor.
Cata et al Dovepress
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controlled trial (RCT) in women having a radical hyster-
ectomy and compared the effects of lidocaine versus pla-
cebo on peripheral blood lymphocytes. The postoperative
proliferative rate of lymphocytes was higher in patients
treated with lidocaine.55 The authors speculated that lido-
caine protected lymphocytes by preserving the IFN-g/IL-4
ratio and by decreasing inflammation, as demonstrated by
lower circulating concentrations of the high mobility
group box-1 protein.55 Similarly, patients with abdominal
pain had a preserved CD4/CD8 ratio, and normal T and B
cell counts after injection of 1.5 mg/kg of lidocaine.54
Local (Infiltration or Intravenous) vs
General Anesthesia: Human Studies
To date, there is no strong evidence from human studies
indicating that local anesthesia modifies oncologic out-
comes after cancer surgery (Table 1). Schalengenhauff
et al included 4329 patients with melanoma and showed
that the use of general anesthesia was associated with a
decreased survival rate.56 A more recent retrospective
study suggests that tumescent local anesthesia, in compar-
ison to general anesthesia, is associated with longer
metastasis-free survival also after melanoma surgery.
However, overall and disease-free survival were not
affected.57
Zhang et al recently assessed the impact of intravenous
lidocaine on cancer progression. The authors reported that
the intraoperative use of lidocaine was associated with
longer overall survival in patients undergoing pancreatic
cancer surgery.58 Several randomized controlled trials are
being conducted in patients with breast (NCT01204242;
NCT01916317), pancreatic (NCT0408278), lung
(NCT04074460) and colorectal (NCT04074460) cancers.
Regional vs Opioid-Based Analgesia:
Humans Studies
Since 2008 there has been an increase in human studies
testing the impact of regional anesthesia on cancer recur-
rence or recurrence-free survival after surgery.9,56,59-89 The
findings are controversial.8,59,90 However, a recent RCT
could not confirm the anti-cancer effects of regional
anesthesia in women undergoing breast cancer surgery.9
Patients were randomized to either regional anesthesia
(preferentially paravertebral block) with propofol sedation
Figure 3 Effect of local anesthetics on immune and inflammatory cells. Local anesthetics modulate the activity of different immune cells. They potentiate natural killer cells
cytotoxicity, facilitate antigen presentation, and have shown to modulate the function of neutrophils, macrophages, and dendritic cells.
Abbreviations: LA, local anesthetics; TNF, tumor necrosis factor.
Dovepress Cata et al
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Table 1 Summary of Clinical Studies, Systematic Reviews and Meta-Analysis on the Impact of Regional Anesthesia/Analgesia in Cancer
Outcomes
Type of Cancer Author
(Year)
Type of
Study
Intervention Overall Survival Recurrence-Free Survival
Breast Sessler et al
(2019)9
RCT PVB-GA vs GA No difference No difference
Breast Perez-
Gonzalez
(2017)59
SR (6 studies) PVB-GA vs GA No difference 1 study showed benefit of PVB-GA, 1
study showed negative impact of PVB-
GA, 4 studies showed no difference
Multiple (Breast,
prostate,
gastroesophageal,
and colorectal)
Ma (2014)90 MA (10
studies)
EA-GA vs GA Not studied No difference overall. No difference for
colorectal alone. For prostate cancer, an
increased survival with EA-GA was
found.
Colorectal Cummings
(2012)61
Retrospective EA-GA vs GA No difference Increased with GA-EA
Colorectal Gottschalk
(2010)62
Retrospective EA-GA vs GA Not studied No difference
Colorectal Gupta
(2011)63
Retrospective EA-GA vs Spinal
vs GA
Increased for rectal
cancer, no difference for
colon cancer
Not studied
Colorectal Day (2012)64 Retrospective EA-GA vs Spinal
vs GA
No difference No difference
Colorectal Kim (2016)65 RCT LA wound
infiltration vs
IVPCA
Not studied No difference
Colorectal liver
metastasis
Zimmitti
(2016)66
Retrospective EA-GA vs GA No difference Increased with EA-GA
Colorectal liver
metastasis
Gao (2019)67 Retrospective EA-GA vs GA Not studied Increased with GA
Gastroesophageal Perez-
Gonzalez
(2018)69
SR (6 studies) EA-GA vs GA 3 studies showed benefit
of EA-GA
1 study showed benefit of EA-GA
Glioblastoma Zheng
(2017)70
Retrospective Scalp block vs
No block
Not studied Increased with scalp block
Glioblastoma Cata (2018)71 Retrospective Scalp block vs
No block
No difference No difference
Hepatocellular Lai (2012)72 Retrospective EA vs GA Not studied Increased with GA
Multiple (Intra-
abdominal,
Prostate and
Colorectal)
Cakmakkaya
(2014)89
MA (4 RCTs
subanalysis
studies)
EA-GA vs GA No difference No difference
Laryngeal and
Hypopharyngeal
Merquiol
(2013)73
Retrospective EA-GA vs GA Increased with EA Increased with EA
(Continued)
Cata et al Dovepress
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or sevoflurane/opioid-based general anesthesia.9 It can be
speculated that regional anesthesia probably did not pro-
duce a robust immunomodulatory or anti-inflammatory
effect and/or, the concentrations of local anesthetics in
micrometastatic niches may not have been high enough
to produce significant effects.91–93 In line with this notion,
Kim et al concluded that continuous local wound infiltra-
tion did not impact one-year recurrence rate after color-
ectal cancer surgery despite a statistically significant
improvement in NK cell function postoperatively.65
Another factor was the short-term exposure to the inter-
vention. Perioperative immune suppression and inflamma-
tion can last beyond the “protective” effects of regional
anesthesia. Our group demonstrated in patients having
major oncologic surgery, the serum IL-6 levels do not
return to preoperative concentrations even two weeks
after surgery.94 Furthermore, the immune “protective”
effects attributed to regional anesthesia in sub-studies of
Table 1 (Continued).
Type of Cancer Author
(Year)
Type of
Study
Intervention Overall Survival Recurrence-Free Survival
Lung Cata (2013)74 Retrospective EA vs PCA vs
EA-IVPCA
No difference No difference
Lung Lee (2017)75 Retrospective EA vs PVB vs
IVPCA
Increased with PVB than
any other technique. EA
and PCA were not
different.
No difference
Melanoma Schlagenhauff
(2000)56
Retrospective LA vs GA Decreased with GA Not studied
Melanoma Gottschalk
(2012)78
Retrospective Spinal vs GA No difference Not studied
Ovarian De Oliveira
(2011)79
Retrospective EA (intra and
postop)-GA vs
Postop-only EA
vs IVPCA
Not studied Increased with EA-GA
Ovarian Lin (2011)80 Retrospective EA vs GA-IVPCA Increased with EA Not studied
Ovarian Capmas
(2012)81
Retrospective EA vs No EA No difference No difference
Ovarian Lacassie
(2013)82
Retrospective EA vs No EA No difference No difference
Ovarian Tseng
(2018)83
Retrospective EA vs IV-PCA Increased with EA Increased with EA
Ovarian Zhong
(2019)84
Retrospective EA vs GA-IVPCA No difference Not studied
Ovarian Elias (2015)85 Retrospective EA-GA vs GA Not studied No difference
Multiple (Ovarian,
Gastrointestinal,
Prostate, Breast)
Grandhi
(2017)86
MA (28
observational
studies)
RA vs GA No difference No difference
Prostate Lee (2015)87 MA (10
retrospective
studies)
EA vs Opioid-
based analgesia
Increased with EA No difference
Abbreviations: EA, epidural anesthesia/analgesia; IV-PCA, intravenous patient-controlled analgesia; GA, general anesthesia; RA, regional anesthesia/analgesia; RCT,
randomized-controlled trial; LA, local anesthetic; PVB, paravertebral block; MA, meta-analysis; SR, systematic review.
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Sessler’s trial indicate that such benefits were not clini-
cally relevant.95,96 Other studies have been designed to test
whether regional anesthesia can improve survival or
reduce recurrence after bladder (NCT:03597087), non-
small cell lung cancer (NCT02840227), colorectal
(NCT02786329), and pancreas (NCT03245346).
In summary, the available evidence indicates that the
impact of regional anesthesia on cancer recurrence might
be negligible or not existent. It remains unknown whether
perioperative intravenous lidocaine infusion has any
impact on cancer progression.
General Anesthetics and Cancer
Progression
Volatile Anesthetics
General anesthetics modify intracellular signaling mechan-
isms involved in metastasis. Isoflurane (1%-2%) increases
migration and invasion of lung cancer cells by promoting
Akt/mTOR activation and by promoting the release of
MMPs.97 In ovarian cancer cells, two-hour exposure to
isoflurane (1.7 MAC), sevoflurane (1.7 MAC), or desflur-
ane (1.7 MAC) stimulated the mRNA expression of
VEGF-A, CXCR2, TGF-β and MMP-11, which correlated
with increased cell migration.98 Also, in ovarian cancer
cells, isoflurane (2%) increased the release of VEGF,
angiopoietin-1 and MMP-2, and 9.99 Sevoflurane (3.6%)
stimulated the metastatic potential of renal cancer cells and
induced their chemo-resistance to cisplatin. These pro-
metastatic effects were linked to an increase in the expres-
sion of TGF-B1, TGF-BRII and downregulation of
Smad3.100 In a melanoma mice model, isoflurane (1.3
MAC) anesthesia promoted pulmonary metastasis.101
As mentioned previously, platelets may play a critical
role in CTCs’ ability to survive in the bloodstream and
attached the endothelium. Lung cancer cells co-cultured
with platelets obtained from patients anesthetized with
sevoflurane or isoflurane showed increased invasive prop-
erties compared to cancer cells incubated with control
platelets.102 Similarly, the culture of colorectal or breast
cancer cells with serum obtained from patients receiving
sevoflurane anesthesia promoted cell survival in compar-
ison to the serum from propofol-treated patients.103,104
Volatile anesthetics can also impair the immune sur-
veillance system. In animals, volatile anesthetics inhibit
the function of NK cells, which correlates with an
increased metastatic burden.105 A reduction in the expres-
sion of the adhesion molecule leukocyte-associated
antigen-1 and decrease in cell-to-cell contact with their
target cancer cells has been implicated in the suppressive
effects of isoflurane and sevoflurane on NK cells’ activity.-
106 Interestingly, Meier et al suggested that the impact of
volatile anesthetics such as isoflurane on the immune
system are sex-depended.107 For instance, when male
mice were treated with isoflurane, the author observed
not only faster tumor growth compared to controls but
also faster tumor growth compared to female
counterparts.107 The investigators demonstrated that an
immune-mediated mechanism was implicated in their find-
ings since melanoma growth was absent in mice lacking
functional T and B cells.107
In vitro and animal studies have also demonstrated that
general anesthetics may have anti-metastatic effects.108,109
High concentrations (5% and 10%) of sevoflurane inhib-
ited migration and invasion of osteosarcoma cells, which
was associated with the inhibition of EMT markers,
including fibronectin and N-cadherin.108 Similarly, sevo-
flurane (4.1%) inhibited glioma cell migration by inducing
the expression of miR-124-3p and suppressing ROCK
signaling.109 Colorectal cancer cells also exposed to 1%
of sevoflurane showed impaired migration and invasion;
an effect that was mediated by inhibition of both, miR-203
expression and ERK signaling.110 Under in vitro hypoxic
conditions, sevoflurane (3.5%) suppressed the ability of
lung cancer cells to migrate and invade the extracellular
matrix by inhibiting the expression of (hypoxia-inducible
factor) HIF-1α, which resulted in low levels of XIAP and
survivin.111 However, Gallyas et al could not demonstrate
that isoflurane influenced the expression of HIF-1α in
renal cancer cells.112
Propofol
Propofol is the most common hypnotic used for TIVA.
Most in vitro and in vivo animal studies indicate that
propofol has significant anti-metastatic effects.113,114 One
of the proposed mechanisms is the downregulation of the
STAT3/HOTAIR signaling pathway, which suppresses
transcription factors Slug and HIF-1α and induces silen-
cing of the NET1 gene; all changes associated with
decreased migration and invasion in cancer cells. A second
mechanism involves the upregulation of miR-124-3p.1,
miR-135b, miR-361, miR-410-3p, miR-328, and lncRNA
DGCR5. A consequence of those epigenetic changes is in
vitro inhibition of EMT, which correlates with low levels
of N-cadherin and MMPs.113
Cata et al Dovepress
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Table 2 Summary of Clinical Studies Comparing TIVA vs Inhalational Anesthesia with Respect to Cancer Outcomes
Type of Cancer Author
(Year)
Type of
Study
Intervention Overall Survival Recurrence-Free Survival
Appendiceal (HIPEC) Cata
(2019)128
Retrospective TIVA (Opioid-
sparing) vs
Inhalational-
Opioid
No difference No difference
Breast Sessler
(2019)9
RCT
subanalysis
TIVA vs
Inhalational
No difference No difference
Breast Lee
(2016)129
Retrospective TIVA vs
Inhalational
No difference Increased with TIVA
Breast Yoo
(2019)130
Retrospective TIVA vs
Inhalational
No difference No difference
Breast Yan
(2018)125
RCT (Not
powered for
OS or RFS)
TIVA vs
Inhalational
No difference No difference
Cholangiocarcinoma Lai
(2019)131
Retrospective TIVA vs
Inhalational
Increased with
TIVA
TIVA group showed a decreased rate of
metastasis.
Colorectal Wu
(2018)132
Retrospective TIVA vs
Inhalational
(Desflurane-
specific)
Increased with
TIVA
Not studied
Esophageal Jun
(2017)133
Retrospective TIVA vs
Inhalational
Increased with
TIVA
Increased with TIVA
Gastric Zheng
(2018)134
Retrospective TIVA vs
Inhalational
Increased with
TIVA
Not studied
Gastric Oh
(2019)135
Retrospective TIVA vs
Inhalational
No difference No difference
Glioblastoma Cata
(2017)136
Retrospective Isoflurane ±
Propofol vs
Desflurane ±
Propofol
No difference No difference
Hepatocellular Lai
(2019)137
Retrospective TIVA vs
Inhalational
(Desflurane-
specific)
Increased with
TIVA
Increased with TIVA
Lung Oh
(2018)138
Retrospective TIVA vs
Inhalational
No difference No difference
Lung Xu
(2017)139
RCT (Not
powered for
OS or RFS)
TIVA vs
Epidural/
Inhalational
No difference No difference
Multiple (Breast,
Esophageal, Lung)
Yap
(2019)140
MA (10
studies)
TIVA vs
Inhalational
Increased with
TIVA
Pooled data from 6 studies showed increased
with TIVA
(Continued)
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Adhesion molecules located on the surface of endothe-
lial cells are needed to initiate TEM. HUVEC cells treated
with different concentrations (5, 25, and 50 µM) of pro-
pofol showed low levels of the adhesion molecules
E-selectin, VCAM-1, and ICAM-1. These changes in the
expression of the adhesion molecules correlated with a
reduction in the expression of HIF-1α, and inhibition of
Akt and CaMKII phosphorylation.114 Propofol also has
anti-angiogenesis effects as demonstrated in experiments
in which it suppressed the invasion of endothelial cells and
vessel formation.115
The proposed mechanisms behind the anti-angiogenic
effects of propofol include the downregulation of S100A4
in endothelial cells and inhibition of the release of VEGF
from cancer cells.115,116 Sen et al conducted an RCT to
investigate the effect of propofol in combination with
regional analgesia (in comparison to sevoflurane anesthe-
sia) on serum concentrations of VEGF in patients having
lung cancer surgery.117 Patients receiving sevoflurane had
significantly higher concentrations of VEGF.117 Lastly, a
proteomic analysis from head and neck cancers demon-
strated that the tumors from patients who received sevo-
flurane anesthesia had higher expression HIF-2α and
phosphorylated p38 MAPK in comparison to those receiv-
ing propofol.118
Propofol can protect against immunosuppression by
promoting cytotoxicity activity of NK cells, decreasing
pro-inflammatory cytokines and inhibiting prostaglandin
E2 (PGE2) and cyclooxygenase (COX) activity. In vitro,
propofol stimulated the function and triggered the prolif-
eration of NK cells obtained from healthy subjects and
patients with cancer. Such effect on NK cells has been
linked to an increase in the expression of granzyme B,
IFNγ, and activating surface receptors (CD16, NKp30,
NKp44, and NKG2D) as well as a reduction in the forma-
tion of PGE2.119–121 The beneficial effect of propofol in
tumor metastasis has been demonstrated in animals. When
rats having surgery were anesthetized with propofol the
function of NK cells remained unchanged and metastatic
formation was lower than animals receiving volatile
anesthetics.105
In women undergoing breast or cervical cancer surgery,
the use of propofol for TIVA in combination with regional
anesthesia increased the number of NK and T helper cells
in the primary tumor tissue and it was associated with
significantly less lymphopenia.96 Similar findings were
Table 2 (Continued).
Type of Cancer Author
(Year)
Type of
Study
Intervention Overall Survival Recurrence-Free Survival
Multiple (Breast,
Gastrointestinal,
Gynecological,
Sarcoma, Urologic,
Other)
Wigmore
(2016)6
Retrospective TIVA vs
Inhalational
Increased with
TIVA
Not studied
Multiple (Breast,
Gastrointestinal, Liver,
Lung)
Hong
(2019)141
Retrospective TIVA vs
Inhalational
No difference Not studied
Multiple (Breast,
Gastrointestinal,
Urologic, Glioma, Lung)
Jin
(2019)142
MA (12
studies)
TIVA vs
Inhalational
Pooled effects
favor TIVA, not
individualized by
cancer type.
Pooled data from 5 studies on recurrence
showed no significant difference. TIVA is
favored in breast cancer. Pooled data specifically
on RFS on 3 studies favor TIVA.
Ovarian Elias
(2015)85
Retrospective Inhaled
Anesthesia
(Sevoflurane/
Desflurane) vs
TIVA
Not studied Increased with desflurane
Abbreviations: RCT, randomized controlled trial; HIPEC, hyperthermic intraperitoneal chemotherapy; TIVA, total intravenous anesthesia; OS, overall survival; RFS,
recurrence-free survival; MA, meta-analysis.
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observed in circulating lymphocytes of surgical patients
with tongue cancer who received TIVA in comparison to
sevoflurane.122,123 In contrast two independent groups of
investigators, did not observe any significant changes cyto-
kines (IL-6, IL-10, and IL-12 TGF- β) and in regulatory T
cell cluster differentiation in women randomized to have
breast cancer surgery under TIVA or sevoflurane general
anesthesia.124,125 Similarly, inflammatory and immune
scores were not different between patients who received
general volatile versus TIVA for pancreatic cancer surgery
or during cytoreduction with hyperthermic intraperitoneal
chemotherapy.126,127
TIVA vs Volatile Anesthesia: Human Studies
Because of the anti-metastatic effects of TIVA in experimen-
tal conditions, there has been a growing interest in translating
such beneficial effects into human studies.6,9,85,125,128-142
The most extensive study was conducted by Wigmore et al,
who retrospectively reviewed the impact of propofol-based
general anesthesia vs volatile anesthesia in more than 7000
patients.6 The authors reported a significant benefit in overall
survival (HR 95% CI: 1.59, 1.30–1.95) in patients receiving
propofol, even after adjusting for metastatic disease.6 Several
much smaller retrospective studies have demonstrated simi-
lar results (Table 2). In 2019, a meta-analysis of 10 retro-
spective studies concluded that the use of TIVA during
cancer surgery is associated with significant improvements
in recurrence-free and overall survival.140 However, TIVA
was associated with the most significant impact on the survi-
val of patients with gastrointestinal malignancies.140 Since
the meta-analysis publication, two retrospective studies that
included over 2000 patients did not show any association
between TIVA and longer survival. Also, data from an RCT
(TIVA vs sevoflurane anesthesia) of patients undergoing
breast cancer surgery could not demonstrate differences in
2 years recurrence-free and overall survival. However, survi-
val was not the primary endpoint of the study, which also
lacked significant statistical power.125 Our group investigated
differences in survival in patients receiving different volatile
anesthetics during glioblastoma surgery.136 We observed no
association between the use of desflurane or isoflurane in
progression-free and overall survival.136
The VAPOR-C trial (NCT04074460) is a RCT
designed to investigate the effect of TIVA versus sevoflur-
ane anesthesia on cancer recurrence in patients having
surgery for lung or colorectal cancers.143 The GA-
CARES (NCT03034096) study is also a large clinical
trial that will randomize patients to TIVA versus volatile
anesthesia. The primary endpoint is all-cause mortality.
Similar studies also being conducted in patients with pan-
creatic (NCT03447691) and breast (NCT02839668)
cancers.
Conclusion
The perioperative period is a time of vulnerability for
patients with cancer because it can promote the seeding
of CTCs or the growth of micrometastatic tumors. The
evidence from experimental laboratory studies demon-
strates that anesthetics can modulate the metastatic beha-
viors of cancer cells. Anesthetics can also affect immune
surveillance and inflammatory responses. Nevertheless, it
is less clear about the actual clinical relevance of such
changes in patients with cancer progression and patient’s
survival.
We think that the strength of evidence is weak to
recommend the use of TIVA to improve cancer-related or
overall survival after oncologic surgery. As for regional
anesthesia, there is strong evidence to conclude that the
impact of paravertebral blocks does not influence cancer
recurrence after breast cancer surgery. The findings of
ongoing and future randomized control trials will bring
light on whether an anesthetic technique modifies the long-
term survival of patients who had surgery for cancer.
Disclosure
The authors declare no conflicts of interest.
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